Dimitrios A. Pappas, Joan M. Bathon, Delphine Hanicq, Uma Yasothan, Peter Kirkpatrick

Research output: Contribution to journalArticlepeer-review


Golimumab (Simponi; Centocor Ortho Biotech), a fully human antibody that is specific for tumour necrosis factor, was approved by the US FDA for the treatment of rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis in April 2009.

Original languageEnglish (US)
Pages (from-to)695-696
Number of pages2
JournalNature Reviews Drug Discovery
Issue number9
StatePublished - Sep 14 2009

ASJC Scopus subject areas

  • Pharmacology
  • Drug Discovery

Fingerprint Dive into the research topics of 'Golimumab'. Together they form a unique fingerprint.

Cite this